1. Patent ReviewFor reprint orders, please contact [email protected] A to Z of pharmaceuticalcocrystals: a decade of fast-movingnew science and patentsÖrn Almarsson*1,…

Slide 1FDA/Industry Workshop September 14-16, 2005 Critical Path Initiative: What it means for pharmaceutical industry statisticians Walter Offen, Lilly Brenda Gaydos, Lilly…

Slide 1An Update on FDAs Critical Path Initiative Statistical Contributions Robert T. ONeill Ph.D. Director, Office of Biostatistics Center for Drug Evaluation and Research…

1. Evaluating the value of research-by-consortium Mark David Lim, PhD 2014 Science of Team Science August 6, 2014 2. Standardized tools = added efficiency Drug discovery…

Hashim Khan Saturday, 2012 • 25-60% of patients – benefit from drugs • 2 million ADR’s & 100,000 death US alone • Drug toxicity- 4th to 6th, causing • leading…

Slide 11 Overview of Pharmaceutical Technology and Education Areas: Industrialization Pharmaceutical Technology Manufacturing Science Pharmaceutical Engineering Education…

Slide 1 Cellular Tissue and Gene Therapies Research Site Visit Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies September 29, 2005 Slide…

The ACTION Public-Private Partnership: Background, Rationale, and Objectives Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia, and Addiction Products CDER,…

Oncology Dose Finding A Case Study: Intra-patient Dose Escalation Jonas Wiedemann, Meghna Kamath Samant & Dominik Heinzmann, pRED Biostatistics, Valerie Cosson &…

The Critical Path Opportunities for Efficiency in Development Robert J. Temple, M.D. Associate Director for Medical Policy Center for Drug Evaluation and Research U.S. Food…